Cardiovascular and Respiratory Pathology/Other Systemic Diseases

Cardiovascular pathophysiology

Antonio Ordóñez Fernández
Antonio Ordóñez Fernández
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla

Laboratory: 113
Tarik Smani Hajami
Tarik Smani Hajami
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla

Laboratory: 113

Antonio Ordóñez Fernández

Back to program
  1. Group members
  2. Research areas
  3. Publications

Group: Cardiovascular pathophysiology

Group members Cardiovascular pathophysiology
  • Ávila Medina, Javier.Ldo en Bioquímica. Predoctoral.
  • Barón Esquivia, Gonzalo.Doctor en Medicina. FEA (HUVR).
  • Calderón Sánchez, Eva.Doctora en Biología. Posdoctoral.
  • Cantero Pérez, Eva M.Lda. en Medicina
  • del Toro Estévez, Raquel.Doctora en Biología
  • Diaz Carrasco, Ignacio.Ldo. en Biología. Predoctoral.
  • Díaz de la Llera, Luis Salvador.Ldo. en Medicina
  • Domínguez Rodríguez, Alejandro.Ldo. en Biología. Predoctoral.
  • Falcón Boyano, Debora.Doctora en Biologia
  • Galeano Otero, Isabel Mª.Investigadora Predoctoral FPU
  • Gutiérrez Carretero, Encarnación.Doctora en Medicina. FEA (HUVR).
  • Hinojosa Pérez, Rafael.Doctor en Medicina. FEA (HUVR).
  • Jiménez López, Ignacio.Jefe de Servicio, HUVR
  • Lage Calle, Ernesto.Ldo. en Medicina. FEA (HUVR).
  • López-Haldon, José.Doctor en Medicina. FEA (HUVR).
  • Martínez Martínez, Angel.Doctor en Medicina. Jefe de Servicio (HUVR).
  • Méndez Santos, Ana.FEA HUVR
  • Ordóñez Fernández, Antonio.MD/PhD. Head of Section/Associate Professor (HUVR/University of Seville).
  • Pedrote Martínez, Ángel A. .Ldo. en Medicina
  • Sánchez de Rojas de Pedro, Eva.Técnico en Radiodiagnóstico
  • Sánchez González, Ángel.Doctor en Medicina. Jefe Unidad Hemodinámica (HUVR).
  • Sempere Bordes, Lluis.Doctor en Biología. Técnico.
  • Smani Hajami, Tarik.Profesor Titular en el Departamento de Fisiología Médica y Biofísica. Universidad de Sevilla
  • Urbano Morales, José Ángel.Doctor en Medicina
  • Valverde Pérez, Israel.Doctor en Medicina

Research areas

Our research is carried out in the clinical area of cardiovascular diseases, focussing our main interests on the analysis of the molecular and cellular mechanisms that participate in the pathophysiological behaviour and in the development of cardiovascular diseases. Our objective is to generate knowledge by which new therapeutic strategies can be designed to deal with different cardiovascular pathologies. Our current research is focussed on three basic areas:


1. Molecular pathophysiology and molecular mechanisms of adaptation of the heart to episodes of ischemia-reperfusion (ischemic preconditioning). We are characterizing the endogenous mechanisms of adaptation which are triggered upon an episode of ischemia-reperfusion, aiming to potentiate this adaptation by modulating new molecular targets such as iPLA2 during ischemia.

2. Corticotropin releasing factor receptor II signalling pathway: Potentiation of endogenous protection against Ischemia-Reperfusion syndrome. The orphan G protein-coupled receptors (GPCRs) are activated by a wide range of vasoactive peptides, some of which are released by organisms in response to ischemia.
The activation of these receptors involves cellular signalling pathways that ultimately lead to adaptation of the heart against prolonged or chronic ischemia and the consequent reperfusion. We aim to perform studies on these possible therapeutic targets to attenuate myocardial damage in clinical situations of ischemia-reperfusion (angioplasty, fibrinolysis, AMI, cardiac transplant).

3. Regulation of coronary vascular tone in response to ischemic events. Involvement of new neuropeptide-dependent signalling pathways. We will highlight the physiological and pathological importance of calcium entry through cation channels regulated by store-operated channels (SOC), their intercommunication with voltage-dependent Ca2+ channels and their modulation of coronary artery tone during a period of hypoxia-reoxygenation. We will study the effects of new neuropeptides on coronary vascular tone via Ca2+ channel regulation.

4. Significance of endothelial dysfunction, oxidative stress and inflammation on the appearance of cardiovascular events in a population with high-risk ischemic cardiopathy. The loss of endothelium-dependent dilation on the circulation is associated with cardiovascular risk factors and with the appearance of adverse cardiovascular events, and improves with those therapies that reduce vascular risk. In this line of work the association is established between cardiovascular risk factors and the deterioration of endothelial function.


Characterisation of new early biomarkers of low-grade heart failure: Urotensin-II involvement in the stratification of the risk and therapeutic management of heart failure.

Cardiac failure involves the activation of several neurohormonal systems. Recently urotensin-II (U-II) has emerged as a more powerful vasoactive peptide within the cardiovascular system. The characterisation of urotensin-II as an early cardiac biomarker in heart failure and the determination of its levels in the plasma of patients could serve as an important diagnostic alternative. This is the primary target of this research line. The U-II signalling pathway in coronary arteries is also determined; the involvement of iPLA2 and SOC channels in its mechanism of action will be studied.


1. Cardio-protection in heart transplantation. The scenario that best demonstrates and clarifies the mechanisms that take part in myocardial protection is during "induced global ischemia" which is necessary for the conservation of the donor heart during the transplantation procedure.

The clinical result of the transplants depends in part on the quality of the graft. One of the most influential factors is myocardial dysfunction in the donor heart caused after brain death. The blockade of sympathetic activity induced by brain death improves the haemodynamic behaviour of the donated heart.

2. Clinical trials. Studies carried out to analyse the effectiveness and safety of new immunosuppressors used in the Cardiac Transplant Clinical Program, as well as comparative drug studies for the prevention of both acute and chronic rejection, form part of our high-priority clinical research program.